Identification and characterization of a compound that protects cardiac tissue from human Ether-à-go-go-related gene (hERG)-related drug-induced arrhythmias

Journal of Biological Chemistry

Volumn 287, Issue 47, 2012, Pages 39613-39625

  Potet, Franck ^a   Lorinc, Amanda N ^a   Chaigne, Sebastien ^a   Hopkins, Corey R ^b   Venkataraman, Raghav ^c   Stepanovic, Svetlana Z ^a   Lewis, L Michelle ^b   Days, Emily ^b   Sidorov, Veniamin Y ^c   Engers, Darren W ^b   Zou, Beiyan ^d   Afshartous, David ^a   George, Alfred L ^a,b   Campbell, Courtney M ^b   Balser, Jeffrey R ^a   Li, Min ^d   Baudenbacher, Franz J ^c   Lindsley, Craig W ^b   Weaver, C David ^b   Kupershmidt, Sabina ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELECTROPHYSIOLOGY; GENES; MOLECULES;

'CURRENT; CARDIAC DEATH; CARDIAC TISSUES; CARDIOTOXICITY; DOFETILIDE; DRUG DISCOVERY; HIGH-THROUGHPUT ASSAYS; LANGENDORFF; REPOLARIZATION; SMALL MOLECULES;

ETHERS;

2 (2 BROMOPHENOXY) N (PYRIDIN 3 YL)ACETAMIDE; 2 (NAPHTHALEN 2 YLOXY) N (PYRIDIN 3 YL)ACETAMIDE; 2 [(1 BROMONAPHTHALEN 2 YL)OXY] N (PYRIDIN 2 YL)ACETAMIDE; 2 [(1 BROMONAPHTHALEN 2 YL)OXY] N (PYRIDIN 3 YL)ACETAMIDE; 2 [(1 BROMONAPHTHALEN 2 YL)OXY] N (PYRIDIN 4 YL)ACETAMIDE; 2 [(1 BROMONAPHTHALEN 2 YL)OXY] N (PYRIMIDIN 5 YL)ACETAMIDE; 2 [(1 BROMONAPHTHALEN 2 YL)OXY] N (THIAZOL 5 YL)ACETAMIDE; 2 [(1 BROMONAPHTHALEN 2 YL)OXY] N PHENYLACETAMIDE; 2 [(1 CHLORONAPHTHALEN 2 YL)OXY] N (PYRIDIN 3 YL)ACETAMIDE; 2 [(1 METHYLNAPHTHALEN 2 YL)OXY] N (PYRIDIN 3 YL)ACETAMIDE; 2 [(3 BROMONAPHTHALEN 2 YL)OXY] N (PYRIDIN 3 YL)ACETAMIDE; ANTIARRHYTHMIC AGENT; DOFETILIDE; POTASSIUM CHANNEL HERG; POTASSIUM ION; UNCLASSIFIED DRUG; VU 0405601; VU 0418705; VU 0453656; VU 0453657; VU 0453658; VU 0453659; VU 0453660; VU 0453661; VU 0455653; VU 0455655; VU 0456912;

ANIMAL CELL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CELL MEMBRANE POTENTIAL; CELL STRAIN HEK293; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG SENSITIVITY; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART PROTECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN ETHER A GO GO RELATED GENE; ISOLATED HEART; MALE; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; RABBIT; STRUCTURE ACTIVITY RELATION;

EID: 84869215742     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.380162     Document Type: Article

References (53)

1. Kr potassium channel. Cell 81, 299-307
2. Trudeau, M. C., Warmke, J. W., Ganetzky, B., and Robertson, G. A. (1995) HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269, 92-95
3. Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D., and Keating, M. T. (1995)Amolecular basis for cardiac arrhythmia. HERG mutations cause long QT syndrome. Cell 80, 795-803
4. Hedley, P. L., Jørgensen, P., Schlamowitz, S., Wangari, R., Moolman-Smook, J., Brink, P. A., Kanters, J. K., Corfield, V. A., and Christiansen, M. (2009) The genetic basis of longQTand shortQTsyndromes. A mutation update. Hum. Mutat. 30, 1486-1511
5. + channel. Open-channel block by methanesulfonanilides. Circ. Res. 78, 499-503
6. Drolet, B., Zhang, S., Deschênes, D., Rail, J., Nadeau, S., Zhou, Z., January, C. T., and Turgeon, J. (1999) Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J. Cardiovasc. Electrophysiol. 10, 1597-1604 (Pubitemid 30020497)
7. Potet, F., Bouyssou, T., Escande, D., and Baró, I. (2001) Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K+ channel. J. Pharmacol. Exp. Ther. 299, 1007-1012 (Pubitemid 33104972)
8. Volberg, W. A., Koci, B. J., Su, W., Lin, J., and Zhou, J. (2002) Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther. 302, 320-327 (Pubitemid 34680454)
9. Ridley, J. M., Milnes, J. T., Hancox, J. C., and Witchel, H. J. (2006) Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel. J. Mol. Cell. Cardiol. 40, 107-118 (Pubitemid 43012122)
10. Kannankeril, P., Roden, D. M., and Darbar, D. (2010) Drug-induced long QT syndrome. Pharmacol. Rev. 62, 760-781
11. Hancox, J. C., McPate, M. J., El Harchi, A., and Zhang, Y. H. (2008) The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol. Ther. 119, 118-132
12. Wynia-Smith, S. L., Gillian-Daniel, A. L., Satyshur, K. A., and Robertson, G. A. (2008) hERG gating microdomains defined by S6 mutagenesis and molecular modeling. J. Gen. Physiol. 132, 507-520
13. De Cicco, M., Macor, F., Robieux, I., Zanette, G., Fantin, D., Fabiani, F., Nicolosi, G., Fracasso, A., Toffoli, G., Santantonio, C., Lestuzzi, C., Matovic, M., and Boiocchi, M. (1999) Pharmacokinetic and pharmacodynamic effects of high dose continuous intravenous verapamil infusion. Clinical experience in the intensive care unit. Crit. Care Med. 27, 332-339 (Pubitemid 29113543)
14. Yang, T., Snyders, D., and Roden, D. M. (2001) Drug block of I(kr). Model systems and relevance to human arrhythmias. J. Cardiovasc. Pharmacol. 38, 737-744 (Pubitemid 32983280)
15. Aiba, T., Shimizu, W., Inagaki, M., Noda, T., Miyoshi, S., Ding, W. G., Zankov, D. P., Toyoda, F., Matsuura, H., Horie, M., and Sunagawa, K. (2005) Cellular and ionic mechanism for drug-induced longQTsyndrome and effectiveness of verapamil. J Am. Coll. Cardiol. 45, 300-307 (Pubitemid 40094741)
16. Weaver, C. D., Harden, D., Dworetzky, S. I., Robertson, B., and Knox, R. J. (2004) A thallium-sensitive, fluorescence-based assay for detecting and characterizing potassium channel modulators in mammalian cells. J. Biomol. Screen. 9, 671-677
17. + current by dofetilide. Circ. Res. 72, 75-83
18. Zou, B., Yu, H., Babcock, J. J., Chanda, P., Bader, J. S., McManus, O. B., and Li, M. (2010) Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-a-go-go related gene potassium channels. Assay Drug Dev. Technol. 8, 743-754
19. Zhou, Z., Gong, Q., Ye, B., Fan, Z., Makielski, J. C., Robertson, G. A., and January, C. T. (1998) Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys. J. 74, 230-241 (Pubitemid 28041752)
20. i in intact rabbit cardiac myocytes. Biophys. J. 68, 1453-1460
21. Snyders, D. J., and Chaudhary, A. (1996) High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol. Pharmacol. 49, 949-955 (Pubitemid 26181422)
22. Kamiya, K., Niwa, R., Mitcheson, J. S., and Sanguinetti, M. C. (2006) Molecular determinants of HERG channel block. Mol. Pharmacol. 69, 1709-1716
23. Hondeghem, L. M., Lu, H. R., van Rossem, K., and De Clerck, F. (2003) Detection of proarrhythmia in the female rabbit heart. Blinded validation. J. Cardiovasc. Electrophysiol. 14, 287-294 (Pubitemid 36444471)
24. Hondeghem, L. M., Carlsson, L., and Duker, G. (2001) Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103, 2004-2013 (Pubitemid 32322230)
25. Nattel, S., Duker, G., and Carlsson, L. (2008) Model systems for the discovery and development of antiarrhythmic drugs. Prog. Biophys. Mol. Biol. 98, 328-339
26. Milberg, P., Eckardt, L., Bruns, H. J., Biertz, J., Ramtin, S., Reinsch, N., Fleischer, D., Kirchhof, P., Fabritz, L., Breithardt, G., and Haverkamp, W. (2002) Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation. Fast phase 3 repolarization prevents early after-depolarizations and Torsade de Pointes. J. Pharmacol. Exp. Ther. 303, 218-225
27. Mitcheson, J. S., Chen, J., and Sanguinetti, M. C. (2000) Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J. Gen. Physiol. 115, 229-240
28. Zhou, J., Augelli-Szafran, C. E., Bradley, J. A., Chen, X., Koci, B. J., Volberg, W. A., Sun, Z., and Cordes, J. S. (2005) Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol. Pharmacol. 68, 876-884 (Pubitemid 41206044)
29. + channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation. J. Physiol 509, 129-137
30. Mitcheson, J. S., Chen, J., Lin, M., Culberson, C., and Sanguinetti, M. C. (2000) A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci. U.S.A. 97, 12329-12333
31. Kiehn, J., Lacerda, A. E., Wible, B., and Brown, A. M. (1996) Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 94, 2572-2579 (Pubitemid 26403588)
32. Tseng, G. N., Sonawane, K. D., Korolkova, Y. V., Zhang, M., Liu, J., Grishin, E. V., and Guy, H. R. (2007) Probing the outer mouth structure of the HERG channel with peptide toxin footprinting and molecular modeling. Biophys. J. 92, 3524-3540 (Pubitemid 46698642)
33. Zhang, M., Korolkova, Y. V., Liu, J., Jiang, M., Grishin, E. V., and Tseng, G. N. (2003) BeKm-1 is a HERG-specific toxin that shares the structure with ChTx but the mechanism of action with ErgTx1. Biophys. J. 84, 3022-3036 (Pubitemid 36534464)
34. Fernandez, D., Ghanta, A., Kauffman, G. W., and Sanguinetti, M. C. (2004) Physicochemical features of the hERG channel drug binding site. J. Biol. Chem. 279, 10120-10127 (Pubitemid 38372616)
35. Sánchez-Chapula, J. A., Navarro-Polanco, R. A., Culberson, C., Chen, J., and Sanguinetti, M. C. (2002) Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J. Biol. Chem. 277, 23587-23595 (Pubitemid 34952195)
36. Snchez-Chapula, J. A., Ferrer, T., Navarro-Polanco, R. A., and Sanguinetti, M. C. (2003) Voltage-dependent profile of human ether-a-go-gorelated gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol. Pharmacol. 63, 1051-1058 (Pubitemid 36529923)
37. Sánchez-Chapula, J. A., Navarro-Polanco, R. A., and Sanguinetti, M. C. (2004) Block of wild-type and inactivation-deficient human ether-a-go-go-related gene K+ channels by halofantrine. Naunyn Schmiedebergs Arch. Pharmacol. 370, 484-491 (Pubitemid 40104761)
38. Ridley, J. M., Dooley, P. C., Milnes, J. T., Witchel, H. J., and Hancox, J. C. (2004) Lidoflazine is a high affinity blocker of the HERG K+ channel. J. Mol. Cell Cardiol. 36, 701-705 (Pubitemid 38591603)
39. Lees-Miller, J. P., Duan, Y., Teng, G. Q., and Duff, H. J. (2000) Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes. Involvement of S6 sites. Mol. Pharmacol. 57, 367-374 (Pubitemid 30084514)
40. Schmalhofer, W. A., Swensen, A. M., Thomas, B. S., Felix, J. P., Haedo, R. J., Solly, K., Kiss, L., Kaczorowski, G. J., and Garcia, M. L. (2010) A pharmacologically validated, high capacity, functional thallium flux assay for the human Ether-a-go-go related gene potassium channel. Assay Drug Dev. Technol. 8, 714-726
41. Roden, D. M. (2004) Drug-induced Prolongation of the QT interval. N. Engl. J. Med. 350, 1013-1022
42. Woosley, R. L. (1996) Cardiac Actions of Antihistamines. Annu. Rev. Pharmacol. Toxicol. 36, 233-252
43. Shah, R. R. (2007) Cardiac repolarization and drug regulation. Assessing cardiac safety 10 years after the CPMP guidance. Drug Saf. 30, 1093-1110
44. Brugada, R., Hong, K., Dumaine, R., Cordeiro, J., Gaita, F., Borggrefe, M., Menendez, T. M., Brugada, J., Pollevick, G. D., Wolpert, C., and Burashnikov, E., Matsuo, K., Wu, Y. S., Guerchicoff, A., Bianchi, F., Giustetto, C., Schimpf, R., Brugada, P., Antzelevitch, C. (2004) Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109, 30-35 (Pubitemid 38056017)
45. Brugada, R., Hong, K., Cordeiro, J. M., and Dumaine, R. (2005) Short QT syndrome. CMAJ 173, 1349-1354 (Pubitemid 41713059)
46. Gussak, I., Brugada, P., Brugada, J., Wright, R. S., Kopecky, S. L., Chaitman, B. R., and Bjerregaard, P. (2000) Idiopathic short QT interval. A new clinical syndrome? Cardiology 94, 99-102 (Pubitemid 32110328)
47. Mitcheson, J. S., and Perry, M. D. (2003) Molecular determinants of high affinity drug binding toHERGchannels. Curr. Opin. Drug Discov. Devel. 6, 667-674 (Pubitemid 37287935)
48. Perry, M., Stansfeld, P. J., Leaney, J., Wood, C., de Groot, M. J., Leishman, D., Sutcliffe, M. J., and Mitcheson, J. S. (2006) Drug binding interactions in the inner cavity of HERG channels. Molecular insights from structure-activity relationships of clofilium and ibutilide analogs. Mol. Pharmacol. 69, 509-519 (Pubitemid 43121948)
49. Ficker, E., Jarolimek, W., Kiehn, J., Baumann, A., and Brown, A. M. (1998) Molecular determinants of dofetilide block of HERG K+ channels. Circ. Res. 82, 386-395 (Pubitemid 28101196)
50. + channel mutation. Differential impact on selected class I and class III antiarrhythmic drugs. Br. J. Pharmacol. 155, 957-966
51. Perrin, M. J., Kuchel, P. W., Campbell, T. J., and Vandenberg, J. I. (2008) Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human Ether-à-go-go-related gene channels. Mol. Pharmacol. 74, 1443-1452
52. + channels by vesnarinone. Mol. Pharmacol. 60, 244-253
53. Milnes, J. T., Crociani, O., Arcangeli, A., Hancox, J. C., and Witchel, H. J. (2003) Blockade ofHERGpotassium currents by fluvoxamine. Incomplete attenuation by S6 mutations at F656 or Y652. Br. J. Pharmacol. 139, 887-898 (Pubitemid 36877388)